Alison P Galvani
Overview
Explore the profile of Alison P Galvani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
288
Citations
8294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S
Lancet Reg Health Am
. 2025 Mar;
44:101033.
PMID: 40046840
Background: The current recommendation for MenACWY vaccination against invasive meningococcal disease (IMD) in the United States (US) includes two doses: the first dose at ages 11-12 and a booster dose...
2.
Sumsuzzman D, Ye Y, Wang Z, Pandey A, Langley J, Galvani A, et al.
BMC Infect Dis
. 2025 Feb;
25(1):215.
PMID: 39948450
Background: Understanding the key drivers of SARS-CoV-2 transmission is essential for shaping effective public health strategies. However, transmission risk is subject to substantial heterogeneity related to disease severity, age, sex,...
3.
Ye Y, Pandey A, Bawden C, Sumsuzzman D, Rajput R, Shoukat A, et al.
Nat Commun
. 2025 Jan;
16(1):581.
PMID: 39794317
Integrating prior epidemiological knowledge embedded within mechanistic models with the data-mining capabilities of artificial intelligence (AI) offers transformative potential for epidemiological modeling. While the fusion of AI and traditional mechanistic...
4.
Du Z, Pandey A, Moghadas S, Bai Y, Wang L, Matrajt L, et al.
Nat Med
. 2025 Jan;
31(2):647-652.
PMID: 39789324
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise...
5.
Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults
Shin T, Wells C, Shoukat A, Potter-Schwartz L, Langevin E, Langley J, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2443551.
PMID: 39504021
Importance: Beginning in 2005, the US implemented routine immunization of adolescents with a quadrivalent conjugate vaccine (MenACWY) for the prevention of invasive meningococcal disease (IMD). Objectives: To assess whether MenACWY...
6.
Pandey A, Ye Y, Wells C, Singer B, Galvani A
Proc Natl Acad Sci U S A
. 2024 Oct;
121(43):e2412872121.
PMID: 39405358
Obesity is a major public health crisis in the United States (US) affecting 42% of the population, exacerbating a spectrum of other diseases and contributing significantly to morbidity and mortality...
7.
Ali S, Li Z, Moqueet N, Moghadas S, Galvani A, Cooper L, et al.
Med Decis Making
. 2024 Sep;
44(7):742-755.
PMID: 39305116
Background: Infectious disease (ID) models have been the backbone of policy decisions during the COVID-19 pandemic. However, models often overlook variation in disease risk, health burden, and policy impact across...
8.
Pandey A, Fitzpatrick M, Singer B, Galvani A
Proc Natl Acad Sci U S A
. 2024 Apr;
121(18):e2321494121.
PMID: 38648491
In the absence of universal healthcare in the United States, federal programs of Medicaid and Medicare are vital to providing healthcare coverage for low-income households and elderly individuals, respectively. However,...
9.
Du Z, Wang L, Bai Y, Liu Y, Lau E, Galvani A, et al.
Elife
. 2024 Apr;
13.
PMID: 38622989
Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics...
10.
Wells C, Pandey A, Moghadas S, Fitzpatrick M, Singer B, Galvani A
Ann Intern Med
. 2024 Mar;
177(5):609-617.
PMID: 38527289
Background: The U.S. Food and Drug Administration has proposed administering annual SARS-CoV-2 vaccines. Objective: To evaluate the effectiveness of an annual SARS-CoV-2 vaccination campaign, quantify the health and economic benefits...